Recently diagnosed with HIV? Click here

Viracept (Nelfinavir) being withdrawn in Australia

Story • Jo Watson • 12 June 2007

Following consultation with the Therapeutic Goods Administration, Roche Pharmaceuticals are undertaking a sponsor initiated recall of all batches and presentations of Viracept (Nelfinavir).

The recall has been initiated because of possible contamination of the active substance by an impurity called methane sulfonic acid ethyl ester in the active substance.

For more information on the withdrawl, open the PDF attachment below, or contact Jo Watson (Executive Officer: NAPWA) on (02)8568 0300

AttachmentSize
070608 - Prescribers.pdf46.85 KB
  • Delicious
  • Digg
  • StumbleUpon
  • Reddit
  • Facebook
  • Google
  • Yahoo
  • Technorati
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Story was first published on 12 June 2007 — more than four years ago.

While the content of this story was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more